FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:69 July 6, 1995 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: We describe two cases of corticosteroid-resistant, life-endangering hemangioma treated with vincristine: a benign hemangioendothelioma in a patient with Kasabach-Merritt syndrome and a liver hemangioendothelioma. Mortality rates among patients with these kinds of hemangioma can be as high as 40 percent and may be more than 50 percent if poor prognostic factors are present.^1,2 Corticosteroids are the medical treatment of choice, except for resistant cases,³ which are not infrequent.

The first patient was a nine-month-old baby who presented with a tumor 10 cm in diameter in the left supraclavicular region and a platelet count of 7400 per cubic . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.